Clinical Faculty

Klaus A. Hollmig, M.D.
Assistant Professor of Medicine

M.D., University of Bonn School of Medicine, Germany
Residency, Internal Medicine, University of Missouri at Columbia
Fellowships, Hematology/Oncology, Bone Marrow Transplantation, University of Alabama at Birmingham

Selected Publications:

Bart Barlogie, M.D., Ph.D., Guido Tricot, M.D., Ph.D., Elias Anaissie, M.D., John Shaughnessy, Ph.D.., Frits van Rhee, M.D., Ph.D., Maurizio Zangari, M.D., Klaus Hollmig, M.D. and John Crowley, Ph.D. Thalidomide and Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine,  2006, Volume 354:1021-1030

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Athanasios Fassas, Klaus Hollmig, Mauricio Pineda-Roman, John Shaughnessy, Joshua Epstein, and John Crowley Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood,  April 2006, Vol. 107, No. 7, pp. 2633-2638.

Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Anaissie E, Hollmig K, Tricot G. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004 Apr;33(8):823-8.

Guo BL, Hollmig KA, Lopez RD. Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12. Cancer Immunol Immunother. 2002 Jan;50(11):625-37.

K.A.Hollmig, Stephen Beck and D.C.Doll. eeding Complications in HIV-Positive Haemophiliac Patients Treated with HIV-Protease Inhibitors - A Case Study
Eur J Med Res. ( 2001) Mar 26;6(3):112-4

K.A.Hollmig, D.Söhngen, M.Leschke, G.Kobbe, P.Schneider, R.M.Klein, C.Aul and A.Heyll
Long-Term Survival of Recipients of Allogeneic Bone Marrow Transplantation after Mechanical Ventilation. European Journal of Medical Research (1997) 2: 62 - 66

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.